# Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

> **NCT04309409** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Essen** · enrollment: 374 (estimated)

## Conditions studied

- Malignant Melanoma Stage II

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04309409
- **Lead sponsor:** University Hospital, Essen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2027-09
- **Final completion:** 2028-01
- **Target enrollment:** 374 (ESTIMATED)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04309409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04309409, "Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04309409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*